Ubs Group Ag Biocept Inc Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.24 - $0.62 $915 - $2,365	-3,815 Reduced 46.37%	4,412 $1,000
Q4 2022 Feb 08, 2023	SELL	$0.47 - $0.89 $1,940 - $3,674	-4,129 Reduced 33.42%	8,227 $4,000
Q3 2022 Nov 10, 2022	BUY	$0.75 - $1.2 $9,267 - $14,827	12,356 New	12,356 $11,000
Q2 2022 Aug 10, 2022	SELL	$0.88 - $2.27 $1,885 - $4,864	-2,143 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.83 - $3.97 $3,921 - $8,507	2,143 New	2,143 $5,000
Q4 2021 Feb 14, 2022	SELL	$3.43 - $4.22 $6,805 - $8,372	-1,984 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.39 - $4.34 $6,725 - $8,610	1,984 New	1,984 $8,000

Ticker BIOC
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,922,900
Market Cap $1.18M
Description
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.